Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Heart Failure Reports
Published in: Current Heart Failure Reports 5/2015

01-10-2015 | Comorbidities of Heart Failure (C. Angermann, Section Editor)

Determined to Fail—the Role of Genetic Mechanisms in Heart Failure

Authors: Elham Kayvanpour, Hugo A. Katus, Benjamin Meder

Published in: Current Heart Failure Reports | Issue 5/2015

Login to get access

Abstract

Genetic variants contribute to several steps during heart failure pathophysiology. The mechanisms include frequent polymorphisms that increase the susceptibility to heart failure in the general population and rare variants as causes of an underlying cardiomyopathy. In this review, we highlight recent discoveries made by genetic approaches and provide an outlook onto the role of epigenetic modifiers of heart failure.
Literature
1.
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.CrossRefPubMed
2.•
Maron BJ, Maron MS, Semsarian C. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol. 2012;60:705–15. A very comprehensive review on cardiomyopathies.CrossRefPubMed
3.•
Lopes LR, Rahman MS, Elliott PM. A systematic review and meta-analysis of genotype-phenotype associations in patients with hypertrophic cardiomyopathy caused by sarcomeric protein mutations. Heart. 2013;99:1800–11. A comprehensive meta-analysis on genotype-phenotype associations in HCM.CrossRefPubMed
4.
Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92:785–9.CrossRefPubMed
5.
Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol. 2000;36:2212–8.CrossRefPubMed
6.
Olivotto I, Girolami F, Ackerman MJ, Nistri S, Bos JM, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc. 2008;83:630–8.CrossRefPubMed
7.
Van Driest SL, Ommen SR, Tajik AJ, Gersh BJ, Ackerman MJ. Sarcomeric genotyping in hypertrophic cardiomyopathy. Mayo Clin Proc. 2005;80:463–9.CrossRefPubMed
8.
Tian T, Liu Y, Zhou X, Song L. Progress in the molecular genetics of hypertrophic cardiomyopathy: a mini-review. Gerontology. 2013;59:199–205.CrossRefPubMed
9.
Ingles J, Doolan A, Chiu C, Seidman J, Seidman C, et al. Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling. J Med Genet. 2005;42, e59.PubMedCentralCrossRefPubMed
10.
Kelly M, Semsarian C. Multiple mutations in genetic cardiovascular disease: a marker of disease severity? Circ Cardiovasc Genet. 2009;2:182–90.CrossRefPubMed
11.
Melacini P, Basso C, Angelini A, Calore C, Bobbo F, et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J. 2010;31:2111–23.PubMedCentralCrossRefPubMed
12.
Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:480–7.CrossRefPubMed
13.
Regitz-Zagrosek V, Petrov G, Lehmkuhl E, Smits JM, Babitsch B, et al. Heart transplantation in women with dilated cardiomyopathy. Transplantation. 2010;89:236–44.CrossRefPubMed
14.
15.
Harakalova M, Kummeling G, Sammani A, Linschoten M, Baas AF, et al. A systematic analysis of genetic dilated cardiomyopathy reveals numerous ubiquitously expressed and muscle-specific genes. Eur J Heart Fail. 2015;17:484–93.CrossRefPubMed
16.
Piran S, Liu P, Morales A, Hershberger RE. Where genome meets phenome: rationale for integrating genetic and protein biomarkers in the diagnosis and management of dilated cardiomyopathy and heart failure. J Am Coll Cardiol. 2012;60:283–9.CrossRefPubMed
17.
18.
Haas J, Frese KS, Peil B, Kloos W, Keller A, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. Eur Heart J. 2015;36:1123–35a.
19.
Baksi AJ, Roberts AM, Ware JS, Gulati A, Buchan RJ, et al. Titin: a phenotype-genotype descriptive comparison of dilated cardiomyopathy. J Cardiovasc Magn Reson. 2014;16:O89.PubMedCentralCrossRef
20.
Nagueh SF, Shah G, Wu Y, Torre-Amione G, King NM, et al. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation. 2004;110:155–62.CrossRefPubMed
21.
Becane HM, Bonne G, Varnous S, Muchir A, Ortega V, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol. 2000;23:1661–6.CrossRefPubMed
22.
Posch MG, Perrot A, Geier C, Boldt LH, Schmidt G, et al. Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. Heart Rhythm. 2009;6:480–6.CrossRefPubMed
23.
Brauch KM, Karst ML, Herron KJ, de Andrade M, Pellikka PA, et al. Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J Am Coll Cardiol. 2009;54:930–41.PubMedCentralCrossRefPubMed
24.
Marcus F, Towbin JA, Zareba W, Moss A, Calkins H, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C): a multidisciplinary study: design and protocol. Circulation. 2003;107:2975–8.CrossRefPubMed
25.
26.
Bhonsale A, Groeneweg JA, James CA, Dooijes D, Tichnell C, et al. Impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J. 2015;36:847–55.CrossRefPubMed
27.
Rigato I, Bauce B, Rampazzo A, Zorzi A, Pilichou K, et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. Circ Cardiovasc Genet. 2013;6:533–42.CrossRefPubMed
28.
Bauce B, Basso C, Rampazzo A, Beffagna G, Daliento L, et al. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur Heart J. 2005;26:1666–75.CrossRefPubMed
29.
Groeneweg JA, van der Zwaag PA, Jongbloed JD, Cox MG, Vreeker A, et al. Left-dominant arrhythmogenic cardiomyopathy in a large family: associated desmosomal or nondesmosomal genotype? Heart Rhythm. 2013;10:548–59.CrossRefPubMed
30.
Sen-Chowdhry S, Syrris P, McKenna WJ. Desmoplakin disease in arrhythmogenic right ventricular cardiomyopathy: early genotype-phenotype studies. Eur Heart J. 2005;26:1582–4.CrossRefPubMed
31.
Arad M, Seidman JG, Seidman CE. Phenotypic diversity in hypertrophic cardiomyopathy. Hum Mol Genet. 2002;11:2499–506.CrossRefPubMed
32.
Oliva-Sandoval MJ, Ruiz-Espejo F, Monserrat L, Hermida-Prieto M, Sabater M, et al. Insights into genotype-phenotype correlation in hypertrophic cardiomyopathy. Findings from 18 Spanish families with a single mutation in MYBPC3. Heart. 2010;96:1980–4.CrossRefPubMed
33.
Moolman-Smook J, De Lange W, Corfield V, Brink P. Expression of HCM causing mutations: lessons learnt from genotype-phenotype studies of the South African founder MYH7 A797T mutation. J Med Genet. 2000;37:951–6.PubMedCentralCrossRefPubMed
34.
Ko YL, Tang TK, Chen JJ, Hshieh YY, Wu CW, et al. Idiopathic hypertrophic cardiomyopathy in identical twins. Morphological heterogeneity of the left ventricle. Chest. 1992;102:783–5.CrossRefPubMed
35.
36.
Bai Y, Wang L, Hu S, Wei Y. Association of angiotensin-converting enzyme I/D polymorphism with heart failure: a meta-analysis. Mol Cell Biochem. 2012;361:297–304.CrossRefPubMed
37.
Li X, Li Y, Jia N, Guo S, Chu S, et al. Angiotensin-converting enzyme gene deletion allele increases the risk of left ventricular hypertrophy: evidence from a meta-analysis. Mol Biol Rep. 2012;39:10063–75.CrossRefPubMed
38.
McNamara DM, Holubkov R, Postava L, Janosko K, MacGowan GA, et al. Pharmacogenetic interactions between angiotensin-converting enzyme inhibitor therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. J Am Coll Cardiol. 2004;44:2019–26.CrossRefPubMed
39.
Goldbergova M, Spinarova L, Spinar J, Toman J, Vasku A, et al. Association of two angiotensinogen gene polymorphisms, M235T and G(−6)A, with chronic heart failure. Int J Cardiol. 2003;89:267–72.CrossRefPubMed
40.
Andersson B, Blange I, Sylven C. Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur J Heart Fail. 1999;1:363–9.CrossRefPubMed
41.
Tiret L, Mallet C, Poirier O, Nicaud V, Millaire A, et al. Lack of association between polymorphisms of eight candidate genes and idiopathic dilated cardiomyopathy: the CARDIGENE study. J Am Coll Cardiol. 2000;35:29–35.CrossRefPubMed
42.
Sanderson JE, Yu CM, Young RP, Shum IO, Wei S, et al. Influence of gene polymorphisms of the renin-angiotensin system on clinical outcome in heart failure among the Chinese. Am Heart J. 1999;137:653–7.CrossRefPubMed
43.
Deinum J, van Gool JM, Kofflard MJ, ten Cate FJ, Danser AH. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension. 2001;38:1278–81.CrossRefPubMed
44.
Erdmann J, Guse M, Kallisch H, Fleck E, Regitz-Zagrosek V. Novel intronic polymorphism (+1675G/A) in the human angiotensin II subtype 2 receptor gene. Hum Mutat. 2000;15:487.CrossRefPubMed
45.
Takai E, Akita H, Kanazawa K, Shiga N, Terashima M, et al. Association between aldosterone synthase (CYP11B2) gene polymorphism and left ventricular volume in patients with dilated cardiomyopathy. Heart. 2002;88:649–50.PubMedCentralCrossRefPubMed
46.
Tiago AD, Badenhorst D, Skudicky D, Woodiwiss AJ, Candy GP, et al. An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res. 2002;54:584–9.CrossRefPubMed
47.
Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med. 2002;347:1135–42.CrossRefPubMed
48.
Bruck H, Leineweber K, Temme T, Weber M, Heusch G, et al. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol. 2005;46:2111–5.CrossRefPubMed
49.
Rochais F, Vilardaga JP, Nikolaev VO, Bunemann M, Lohse MJ, et al. Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest. 2007;117:229–35.PubMedCentralCrossRefPubMed
50.
Sandilands AJ, Parameshwar J, Large S, Brown MJ, O’Shaughnessy KM. Confirmation of a role for the 389R > G beta-1 adrenoceptor polymorphism on exercise capacity in heart failure. Heart. 2005;91:1613–4.PubMedCentralCrossRefPubMed
51.
Wagoner LE, Craft LL, Zengel P, McGuire N, Rathz DA, et al. Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J. 2002;144:840–6.CrossRefPubMed
52.
Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, et al. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest. 1998;102:1534–9.PubMedCentralCrossRefPubMed
53.
Smith NL, Felix JF, Morrison AC, Demissie S, Glazer NL, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet. 2010;3:256–66.PubMedCentralCrossRefPubMed
54.
Meder B, Ruhle F, Weis T, Homuth G, Keller A, et al. A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. Eur Heart J. 2014;35:1069–77.CrossRefPubMed
55.
Villard E, Perret C, Gary F, Proust C, Dilanian G, et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. Eur Heart J. 2011;32:1065–76.PubMedCentralCrossRefPubMed
56.
Cappola TP, Li M, He J, Ky B, Gilmore J, et al. Common variants in HSPB7 and FRMD4B associated with advanced heart failure. Circ Cardiovasc Genet. 2010;3:147–54.PubMedCentralCrossRefPubMed
57.•
Garnier S, Hengstenberg C, Lamblin N, Dubourg O, De Groote P, et al. Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: results of a European collaboration assembling more than 2000 patients. Int J Cardiol. 2015;189:105–7. A comprehensive meta-analysis on loci associated with CAD.CrossRefPubMed
58.
Morrison AC, Felix JF, Cupples LA, Glazer NL, Loehr LR, et al. Genomic variation associated with mortality among adults of European and African ancestry with heart failure: the cohorts for heart and aging research in genomic epidemiology consortium. Circ Cardiovasc Genet. 2010;3:248–55.PubMedCentralCrossRefPubMed
59.
60.
Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet. 2010;42:579–89.PubMedCentralCrossRefPubMed
61.
International Consortium for Blood Pressure Genome-Wide Association S, Ehret GB, Munroe PB, Rice KM, Bochud M, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103–9.CrossRef
62.
Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 2010;466:707–13.PubMedCentralCrossRefPubMed
63.
Schunkert H, Konig IR, Kathiresan S, Reilly MP, Assimes TL, et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet. 2011;43:333–8.PubMedCentralCrossRefPubMed
64.
Haas J, Frese KS, Park YJ, Keller A, Vogel B, et al. Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med. 2013;5:413–29.PubMedCentralCrossRefPubMed
65.
Movassagh M, Choy MK, Knowles DA, Cordeddu L, Haider S, et al. Distinct epigenomic features in end-stage failing human hearts. Circulation. 2011;124:2411–22.PubMedCentralCrossRefPubMed
66.
Xiao D, Dasgupta C, Chen M, Zhang K, Buchholz J, et al. Inhibition of DNA methylation reverses norepinephrine-induced cardiac hypertrophy in rats. Cardiovasc Res. 2014;101:373–82.PubMedCentralCrossRefPubMed
67.
Metes-Kosik N, Luptak I, Dibello PM, Handy DE, Tang SS, et al. Both selenium deficiency and modest selenium supplementation lead to myocardial fibrosis in mice via effects on redox-methylation balance. Mol Nutr Food Res. 2012;56:1812–24.PubMedCentralCrossRefPubMed
68.
69.
70.
Hang CT, Yang J, Han P, Cheng HL, Shang C, et al. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature. 2010;466:62–7.PubMedCentralCrossRefPubMed
71.
72.
Karamboulas C, Swedani A, Ward C, Al-Madhoun AS, Wilton S, et al. HDAC activity regulates entry of mesoderm cells into the cardiac muscle lineage. J Cell Sci. 2006;119:4305–14.CrossRefPubMed
73.
Backs J, Worst BC, Lehmann LH, Patrick DM, Jebessa Z, et al. Selective repression of MEF2 activity by PKA-dependent proteolysis of HDAC4. J Cell Biol. 2011;195:403–15.PubMedCentralCrossRefPubMed
74.
Hohl M, Wagner M, Reil JC, Muller SA, Tauchnitz M, et al. HDAC4 controls histone methylation in response to elevated cardiac load. J Clin Invest. 2013;123:1359–70.PubMedCentralCrossRefPubMed
75.
Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, et al. Toward the blood-borne miRNome of human diseases. Nat Methods. 2011;8:841–3.CrossRefPubMed
76.
Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol. 2011;106:13–23.CrossRefPubMed
77.
Tao H, Shi KH, Yang JJ, Huang C, Liu LP, et al. Epigenetic regulation of cardiac fibrosis. Cell Signal. 2013;25:1932–8.CrossRefPubMed
78.
van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A. 2006;103:18255–60.PubMedCentralCrossRefPubMed
79.
Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn 2nd GW. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. Circ Res. 2012;111:521–31.PubMedCentralCrossRefPubMed
80.
Weber M, Baker MB, Moore JP, Searles CD. MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activity. Biochem Biophys Res Commun. 2010;393:643–8.PubMedCentralCrossRefPubMed
81.
Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ, et al. Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients. Eur J Heart Fail. 2013;15:1138–47.CrossRefPubMed
82.
Thum T, Gross C, Fiedler J, Fischer T, Kissler S, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980–4.CrossRefPubMed
83.
Suckau L, Fechner H, Chemaly E, Krohn S, Hadri L, et al. Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation. 2009;119:1241–52.PubMedCentralCrossRefPubMed
84.
85.
Halkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013;123:2143–54.PubMedCentralCrossRefPubMed
Metadata
Title
Determined to Fail—the Role of Genetic Mechanisms in Heart Failure
Authors
Elham Kayvanpour
Hugo A. Katus
Benjamin Meder
Publication date
01-10-2015
Publisher
Springer US
Published in
Current Heart Failure Reports / Issue 5/2015
Print ISSN: 1546-9530
Electronic ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-015-0264-6

Other articles of this Issue 5/2015

Current Heart Failure Reports 5/2015 Go to the issue

Epidemiology of Heart Failure (J. Ho, Section Editor)

Cardiometabolic Disease Leading to Heart Failure: Better Fat and Fit Than Lean and Lazy

Epidemiology of Heart Failure (J. Ho, Section Editor)

Epidemiology of Right Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction

Biomarkers of Heart Failure (W.H.W. Tang, Section Editor)

The Current and Potential Clinical Relevance of Heart Failure Biomarkers

Epidemiology of Heart Failure (J. Ho, Section Editor)

Assessing Risk and Preventing 30-Day Readmissions in Decompensated Heart Failure: Opportunity to Intervene?

Biomarkers of Heart Failure (W.H.W. Tang, Section Editor

Novel Biomarker Approaches for Managing Patients With Cardiac Transplantation
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits